MITOMYCIN , JNJ-42756493, GEMCITABINE
42756493BLC3005
Phase 3 small_molecule active
Quick answer
MITOMYCIN , JNJ-42756493, GEMCITABINE for High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active